Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Indian Science
  4. Volume 1, Issue 1
  5. Article
Volume 1, Issue 1
  • ISSN: 2210-299X
  • E-ISSN: 2210-3007
file format text download EPUB
file format pdf download PDF
side by side viewer icon HTML

Abstract

Background

Pain is a complex physiological and psychological response to a noxious stimulus, sometimes deteriorating a patient’s quality of life. Opioids remain the mainstay treatment modality for chronic pain. Several concerns are raised regarding the long-term use of opioids and the risks associated with their usage. Findings advocate that the longstanding practice of opioid consumption manifests in adverse effects.

Objective

Due to the physiological changes opioids instigate in the gastrointestinal tract, opioidinduced constipation remains a common complication pragmatic in patients undergoing opioid medications. Several therapeutic interventions are made available, and the review describes the overall medications with practical examples, aiding in selecting a treatment plan.

Methods

The method comprises data collection from various search engines like PubMed, ScienceDirect, and SciFinder to get coverage of relevant literature for accumulating appropriate information regarding pain management, opioids, opioid-induced constipation, and its pharmacological interventions.

Results

The thoughtful custom of exploring several options to manage opioid-induced constipation must allow patients to benefit from opioid analgesia.

Conclusion

This paper reviews the role of opioids in pain management, the underlying mechanisms of their action, opioid-induced constipation, and pharmacological therapies, with experimental studies aiding clinicians to optimise treatment plans.

© 2023 Bentham Science Publishers
© 2023 The Author(s). Published by Bentham Science Publisher. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/cis/10.2174/2210299X01666220902112122
2022-09-02
2024-11-22

  • From This Site

    /content/journals/cis/10.2174/2210299X01666220902112122
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cis/1/1/CIS-1-E020922208451.html?itemId=/content/journals/cis/10.2174/2210299X01666220902112122&mimeType=html&fmt=ahah

References

  1. RajaS.N. CarrD.B. CohenM. FinnerupN.B. FlorH. GibsonS. KeefeF.J. MogilJ.S. RingkampM. SlukaK.A. SongX.J. StevensB. SullivanM.D. TutelmanP.R. UshidaT. VaderK. The revised international association for the study of pain definition of pain: Concepts, challenges, and compromises.Pain202016191976198210.1097/j.pain.000000000000193932694387
     [Google Scholar]
  2. TreedeR.D. RiefW. BarkeA. AzizQ. BennettM.I. BenolielR. CohenM. EversS. FinnerupN.B. FirstM.B. GiamberardinoM.A. KaasaS. KosekE. Lavand’hommeP. NicholasM. PerrotS. ScholzJ. SchugS. SmithB.H. SvenssonP. VlaeyenJ.W.S. WangS.J. A classification of chronic pain for ICD-11.Pain201515661003100710.1097/j.pain.000000000000016025844555
     [Google Scholar]
  3. SungH. FerlayJ. SiegelR.L. LaversanneM. SoerjomataramI. JemalA. BrayF. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.202171320924910.3322/caac.2166033538338
     [Google Scholar]
  4. RosenblumA. MarschL.A. JosephH. PortenoyR.K. Opioids and the treatment of chronic pain: Controversies, current status, and future directions.Exp. Clin. Psychopharmacol.200816540541610.1037/a001362818837637
     [Google Scholar]
  5. WHO. Opioid overdose.Available from: https://www.who.int/news-room/fact-sheets/detail/opioid-overdose (Accessed on: 8 June 2022).
  6. Lang-IllievichK. Bornemann-CimentiH. Opioid-induced constipation: A narrative review of therapeutic options in clinical management.Korean J. Pain2019322697810.3344/kjp.2019.32.2.6931091505
     [Google Scholar]
  7. FarmerA.D. HoltC.B. DownesT.J. RuggeriE. Del VecchioS. De GiorgioR. Pathophysiology, diagnosis, and management of opioid-induced constipation.Lancet Gastroenterol. Hepatol.20183320321210.1016/S2468‑1253(18)30008‑629870734
     [Google Scholar]
  8. RanaD. SalaveS. BenivalD. Emerging trends in abuse-deterrent formulations: Technological insights and regulatory considerations.Curr. Drug Deliv.20211834879799
     [Google Scholar]
  9. DubinA.E. PatapoutianA. Nociceptors: The sensors of the pain pathway.J. Clin. Invest.2010120113760377210.1172/JCI4284321041958
     [Google Scholar]
  10. OkuseK. Pain signalling pathways: From cytokines to ion channels.Int. J. Biochem. Cell Biol.200739349049610.1016/j.biocel.2006.11.01617194618
     [Google Scholar]
  11. WHO. Cancer pain relief.Available from: https://apps.who.int/iris/bitstream/handle/10665/43944/9241561009_eng.pdf (Accessed on: 8 June 2022).
  12. WHO. Cancer pain relief : With a guide to opioid availability.Available from: http://apps.who.int/iris/bitstream/handle/10665/37896/9241544821.pdf?sequence=1 (Accessed on: 8 June 2022).
  13. WHO. Cancer pain relief and palliative care in children.Available from: http://apps.who.int/iris/bitstream/handle/10665/42001/9241545127.pdf?sequence=1 (Accessed on: 8 June 2022).
  14. NersesyanH. SlavinK.V. Current aproach to cancer pain management: Availability and implications of different treatment options.Ther. Clin. Risk Manag.20073338140018488078
     [Google Scholar]
  15. AcademyT.A. DentistryP. AffairsC. Pain management in infants, children, adolescents and individuals with special health care needs.Pediatr. Dent.201840632132932074903
     [Google Scholar]
  16. Prescription Opioids DrugFacts | National Institute on Drug Abuse (NIDA).Available from: https://nida.nih.gov/publications/drugfacts/prescription-opioids (Accessed on: 10 Feb 2022).
  17. OmidianA. MastropietroD.J. OmidianH. Routes of opioid abuse and its novel deterrent formulations.J. Dev. Drugs20154517
     [Google Scholar]
  18. CohenB. RuthL.J. PreussC.V. Opioid Analgesics.StatPearlsTreasure Island (FL)StatPearls Publishing2021
     [Google Scholar]
  19. DydykA.M. JainN.K. GuptaM. Opioid Use Disorder.StatPearlsTreasure Island (FL)StatPearls Publishing2021
     [Google Scholar]
  20. ZöllnerC. SteinC. Opioids.Handb. Exp. Pharmacol.2007177177316317087119
     [Google Scholar]
  21. RastogiR. SwarmR.A. PatelT.A. RiouB. Case scenario: Opioid association with serotonin syndrome: Implications to the practitioners.Anesthesiology201111561291129810.1097/ALN.0b013e31823940c022037635
     [Google Scholar]
  22. CrockettS.D. GreerK.B. HeidelbaughJ.J. Falck-YtterY. HansonB.J. SultanS. American Gastroenterological Association Institute guideline on the medical management of opioid-induced constipation.Gastroenterology2019156121822610.1053/j.gastro.2018.07.01630340754
     [Google Scholar]
  23. Center for Substance Abuse TreatmentManaging Chronic Pain in Adults With or in Recovery From Substance Use DisordersSubstance Abuse and Mental Health Services Administration (US)Rockville (MD)2012
     [Google Scholar]
  24. BrownsteinM.J. A brief history of opiates, opioid peptides, and opioid receptors.Proc. Natl. Acad. Sci. USA199390125391539310.1073/pnas.90.12.53918390660
     [Google Scholar]
  25. SimonE.J. Opioid receptors and endogenous opioid peptides.Med. Res. Rev.199111435737410.1002/med.26101104021652044
     [Google Scholar]
  26. LawP.Y. LohH.H. Opioid Receptors.Encyclopedia of Biological Chemistry LennarzW.J. LaneM.D. Second EditionAcademic PressCambridge, Massachusetts2013235435810.1016/B978‑0‑12‑378630‑2.00347‑9
     [Google Scholar]
  27. PasternakG.W. PanY.X. Mu opioids and their receptors: Evolution of a concept.Pharmacol. Rev.20136541257131710.1124/pr.112.00713824076545
     [Google Scholar]
  28. Al-HasaniR. BruchasM.R. Molecular mechanisms of opioid receptor-dependent signaling and behavior.Anesthesiology201111561363138110.1097/ALN.0b013e318238bba622020140
     [Google Scholar]
  29. McDonaldJ. LambertD.G. Opioid receptors.Contin. Educ. Anaesth. Crit. Care Pain200551222510.1093/bjaceaccp/mki004
     [Google Scholar]
  30. ZhangJ. FergusonS.S.G. BarakL.S. BodduluriS.R. LaporteS.A. LawP.Y. CaronM.G. Role for G protein-coupled receptor kinase in agonist-specific regulation of μ-opioid receptor responsiveness.Proc. Natl. Acad. Sci. USA199895127157716210.1073/pnas.95.12.71579618555
     [Google Scholar]
  31. WaldhoerM. BartlettS.E. WhistlerJ.L. Opioid receptors.Annu. Rev. Biochem.200473195399010.1146/annurev.biochem.73.011303.07394015189164
     [Google Scholar]
  32. KasererT. SteinacherT. KainhoferR. ErliF. SturmS. WaltenbergerB. SchusterD. SpeteaM. Identification and characterization of plant-derived alkaloids, corydine and corydaline, as novel mu opioid receptor agonists.Sci. Rep.20201011380410.1038/s41598‑020‑70493‑132796875
     [Google Scholar]
  33. TrescotA.M. DattaS. LeeM. HansenH. Opioid pharmacology.Pain Physician2008112 SupplS133S15310.36076/ppj.2008/11/S13318443637
     [Google Scholar]
  34. AkilH. OwensC. GutsteinH. TaylorL. CurranE. WatsonS. Endogenous opioids: Overview and current issues.Drug Alcohol Depend.1998511-212714010.1016/S0376‑8716(98)00071‑49716935
     [Google Scholar]
  35. BzdegaT. ChinH. KimH. JungH.H. KozakC.A. KleeW.A. Regional expression and chromosomal localization of the delta opiate receptor gene.Proc. Natl. Acad. Sci. USA199390209305930910.1073/pnas.90.20.93058415697
     [Google Scholar]
  36. WadenbergM-L.G. A review of the properties of spiradoline: A potent and selective kappa-opioid receptor agonist.CNS Drug Rev.20039218719810.1111/j.1527‑3458.2003.tb00248.x12847558
     [Google Scholar]
  37. WalshS. StrainE. AbreuM. BigelowG. Enadoline, a selective kappa opioid agonist: Comparison with butorphanol and hydromorphone in humans.Psychopharmacology (Berl.)2001157215116210.1007/s00213010078811594439
     [Google Scholar]
  38. ZaveriN.T. JiangF. OlsenC. PolgarW.E. TollL. Designing bifunctional NOP receptor–mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I.Bioorg. Med. Chem. Lett.201323113308331310.1016/j.bmcl.2013.03.10123623415
     [Google Scholar]
  39. ZaveriN.T. Nociceptin Opioid Receptor (NOP) as a therapeutic target: Progress in translation from preclinical research to clinical utility.J. Med. Chem.201659157011702810.1021/acs.jmedchem.5b0149926878436
     [Google Scholar]
  40. JaneckaA. FichnaJ. JaneckiT. Opioid receptors and their ligands.Curr. Top. Med. Chem.20044111710.2174/156802604345161814754373
     [Google Scholar]
  41. PathanH. WilliamsJ. Basic opioid pharmacology: An update.Br. J. Pain201261111610.1177/204946371243849326516461
     [Google Scholar]
  42. DhawanB.N. CesselinF. RaghubirR. ReisineT. BradleyP.B. PortogheseP.S. HamonM. International Union of Pharmacology. XII. Classification of opioid receptors.Pharmacol. Rev.19964845675928981566
     [Google Scholar]
  43. FreyeE. LevyJ.V. Mechanism of action of opioids and clinical effects. Opioids in Medicine FreyeE. LevyJ.V. SpringerDordrecht20088518710.1007/978‑1‑4020‑5947‑6_2
     [Google Scholar]
  44. VallejoR. BarkinR.L. WangV.C. Pharmacology of opioids in the treatment of chronic pain syndromes.Pain Physician2011414E343E36010.36076/ppj.2011/14/E34321785485
     [Google Scholar]
  45. MachadoT.M. PalattyP.L. Opioid analgesic choices based on pharmacokinetics.J Anesth Pain Med.20161218
     [Google Scholar]
  46. PergolizziJ.V.Jr ChristoP.J. LeQuangJ.A. MagnussonP. The use of Peripheral μ-Opioid Receptor Antagonists (PAMORA) in the management of opioid-induced constipation: An update on their efficacy and safety.Drug Des. Devel. Ther.2020141009102510.2147/DDDT.S22127832210534
     [Google Scholar]
  47. GuptaD.K. KrejcieT.C. AvramM.J. Essential drugs in anesthetic practice. Pharmacokinetics of opioids.Anesth Pharmacol2011509530
     [Google Scholar]
  48. MachelskaH. CelikM.Ö. Advances in achieving opioid analgesia without side effects.Front. Pharmacol.20189138810.3389/fphar.2018.0138830555325
     [Google Scholar]
  49. BoomM. NiestersM. SartonE. AartsL. SmithT.W. DahanA. Non-analgesic effects of opioids: Opioid-induced respiratory depression.Curr. Pharm. Des.201218375994600410.2174/13816121280358246922747535
     [Google Scholar]
  50. RawalH. PatelB.M. Opioids in cardiovascular disease: Therapeutic options.J. Cardiovasc. Pharmacol. Ther.201823427929110.1177/107424841875700929528698
     [Google Scholar]
  51. NeeJ. ZakariM. SugarmanM.A. WhelanJ. HirschW. SultanS. BallouS. IturrinoJ. LemboA. Efficacy of treatments for opioid-induced constipation: Systematic review and meta-analysis.Clin. Gastroenterol. Hepatol.2018161015691584.e210.1016/j.cgh.2018.01.02129374616
     [Google Scholar]
  52. Müller-LissnerS. BassottiG. CoffinB. DrewesA.M. BreivikH. EisenbergE. EmmanuelA. LarocheF. MeissnerW. MorlionB. Opioid-induced constipation and bowel dysfunction: A clinical guideline.Pain Med.201718101837186328034973
     [Google Scholar]
  53. KjellbergF. TramèrM.R. Pharmacological control of opioid-induced pruritus: A quantitative systematic review of randomized trials.Eur. J. Anaesthesiol.200118634635710.1097/00003643‑200106000‑0000211412287
     [Google Scholar]
  54. SterniniC. PatiernoS. SelmerI.S. KirchgessnerA. The opioid system in the gastrointestinal tract.Neurogastroenterol. Motil.200416s2Suppl. 231610.1111/j.1743‑3150.2004.00553.x15357847
     [Google Scholar]
  55. HolzerP. Treatment of opioid-induced gut dysfunction.Expert Opin. Investig. Drugs200716218119410.1517/13543784.16.2.18117243938
     [Google Scholar]
  56. LabiancaR. Sarzi-PuttiniP. ZuccaroS.M. CherubinoP. VellucciR. FornasariD. Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain.Clin. Drug Investig.201232Suppl. 1536310.2165/11630080‑000000000‑00000
     [Google Scholar]
  57. McNicolE. Horowicz-MehlerN. FiskR.A. BennettK. Gialeli-GoudasM. ChewP.W. LauJ. CarrD. Management of opioid side effects in cancer-related and chronic noncancer pain: A systematic review.J. Pain20034523125610.1016/S1526‑5900(03)00556‑X14622694
     [Google Scholar]
  58. SwegleJ.M. LogemannC. Management of common opioid-induced adverse effects.Am. Fam. Physician20067481347135417087429
     [Google Scholar]
  59. YeeJ.D. BerdeC.B. Dextroamphetamine or methylphenidate as adjuvants to opioid analgesia for adolescents with cancer.J. Pain Symptom Manage.19949212212510.1016/0885‑3924(94)90165‑17912710
     [Google Scholar]
  60. DhingraL. AhmedE. ShinJ. ScharagaE. MagunM. Cognitive effects and sedation.Pain Med.201516Suppl. 1S37S4310.1111/pme.1291226461075
     [Google Scholar]
  61. GaneshA. MaxwellL.G. Pathophysiology and management of opioid-induced pruritus.Drugs2007671623232333
     [Google Scholar]
  62. FriedmanJ.D. Dello BuonoF.A. Opioid antagonists in the treatment of opioid-induced constipation and pruritus.Ann. Pharmacother.2001351859117983254
     [Google Scholar]
  63. DahanA. van der SchrierR. SmithT. AartsL. van VelzenM. NiestersM. Averting opioid-induced respiratory depression without affecting analgesia.Anesthesiology201812851027103710.1097/ALN.000000000000218429553984
     [Google Scholar]
  64. ColuzziF. BifulcoF. CuomoA. DauriM. LeonardiC. MelottiR.M. NatoliS. RomualdiP. SavoiaG. CorcioneA. The challenge of perioperative pain management in opioid-tolerant patients.Ther. Clin. Risk Manag.2017131163117310.2147/TCRM.S14133228919771
     [Google Scholar]
  65. BenyaminR. TrescotA.M. DattaS. BuenaventuraR. AdlakaR. SehgalN. GlaserS.E. VallejoR. Opioid complications and side effects.Pain Physician2008211S105S12010.36076/ppj.2008/11/S10518443635
     [Google Scholar]
  66. DuPenA. ShenD. ErsekM. Mechanisms of opioid-induced tolerance and hyperalgesia.Pain Manag. Nurs.20078311312110.1016/j.pmn.2007.02.00417723928
     [Google Scholar]
  67. CroffordL.J. Adverse effects of chronic opioid therapy for chronic musculoskeletal pain.Nat. Rev. Rheumatol.20106419119710.1038/nrrheum.2010.2420357788
     [Google Scholar]
  68. FarmerA.D. DrewesA.M. ChiarioniG. De GiorgioR. O’BrienT. MorlionB. TackJ. Pathophysiology and management of opioid-induced constipation: European expert consensus statement.United European Gastroenterol. J.20197172010.1177/205064061881830530788113
     [Google Scholar]
  69. WebsterL.R. Opioid-induced constipation.Pain Med.201516Suppl. 1S16S2110.1111/pme.1291126461071
     [Google Scholar]
  70. TabbersM.M. DiLorenzoC. BergerM.Y. FaureC. LangendamM.W. NurkoS. StaianoA. VandenplasY. BenningaM.A. Evaluation and treatment of functional constipation in infants and children: Evidence-based recommendations from ESPGHAN and NASPGHAN.J. Pediatr. Gastroenterol. Nutr.201458225827410.1097/MPG.000000000000026624345831
     [Google Scholar]
  71. KlaschikE. NauckF. OstgatheC. Constipation? Modern laxative therapy.Support. Care Cancer2003111167968510.1007/s00520‑003‑0525‑x14505158
     [Google Scholar]
  72. PortalatinM. WinsteadN. Medical management of constipation.Clin. Colon Rectal Surg.201225101201910.1055/s‑0032‑130175423449608
     [Google Scholar]
  73. SchillerL.R. The therapy of constipation.Aliment. Pharmacol. Ther.200115674976310.1046/j.1365‑2036.2001.00982.x11380313
     [Google Scholar]
  74. GarnerCE MatthewsHB BurkaLT PharmacolLTTA Phenolphthalein metabolite inhibits catechol-o-methyltransferase-mediated metabolism of catechol estrogens: A possible mechanism for carcinogenicity.Toxicol. Appl. Pharmacol2000162212413110.1006/taap.1999.8830
     [Google Scholar]
  75. FrenchD. WuA.H.B. Cardiac markers.The Immunoassay Handbook WildD. 4th edElsevier ScienceAmsterdam, Netherlands2013181783110.1016/B978‑0‑08‑097037‑0.00066‑X
     [Google Scholar]
  76. LeppertW. ZajaczkowskaR. WordliczekJ. The role of oxycodone/naloxone in the management of patients with pain and opioid-induced constipation.Expert Opin. Pharmacother.201920551152210.1080/14656566.2018.156186330625013
     [Google Scholar]
  77. MynttinenE. WesterN. LiliusT. KalsoE. MikladalB. VarjosI. SainioS. JiangH. KauppinenE.I. KoskinenJ. LaurilaT. Electrochemical detection of oxycodone and its main metabolites with nafion-coated single-walled carbon nanotube electrodes.Anal. Chem.202092128218822710.1021/acs.analchem.0c0045032412733
     [Google Scholar]
  78. LiuM. WittbrodtE. Low-dose oral naloxone reverses opioid-induced constipation and analgesia.J. Pain Symptom Manage.2002231485310.1016/S0885‑3924(01)00369‑411779668
     [Google Scholar]
  79. SmithK. HoppM. MundinG. BondS. BaileyP. WoodwardJ. BellD. Low absolute bioavailability of oral naloxone in healthy subjects.Int. J. Clin. Pharmacol. Ther.201250536036710.5414/CP20164622541841
     [Google Scholar]
  80. KoopmansG. SimpsonK. De AndrésJ. LuxE.A. WagemansM. Van MegenY. Fixed ratio (2:1) prolonged-release oxycodone/naloxone combination improves bowel function in patients with moderate-to-severe pain and opioid-induced constipation refractory to at least two classes of laxatives.Curr. Med. Res. Opin.201430112389239610.1185/03007995.2014.97135525265132
     [Google Scholar]
  81. PoelaertJ. Koopmans-KleinG. DiohA. LouisF. GorissenM. LogéD. Van Op den boschJ. van MegenY.J.B. Treatment with prolonged-release oxycodone/naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipation.Clin. Ther.201537478479210.1016/j.clinthera.2015.02.01025757607
     [Google Scholar]
  82. BantelC. TripathiS. MolonyD. HeffernanT. OommansS. MehtaV. DickersonS. Prolonged-release oxycodone/naloxone reduces opioid-induced constipation and improves quality of life in laxative-refractory patients: Results of an observational study.Clin. Exp. Gastroenterol.201811576710.2147/CEG.S14391329416370
     [Google Scholar]
  83. JobskiK. KollhorstB. GarbeE. SchinkT. The risk of ischemic cardio- and cerebrovascular events associated with oxycodone–naloxone and other extended-release high-potency opioids: A nested case–control study.Drug Saf.201740650551510.1007/s40264‑017‑0511‑828194654
     [Google Scholar]
  84. SridharanK. SivaramakrishnanG. Drugs for treating opioid-induced constipation: A mixed treatment comparison network meta-analysis of randomized controlled clinical trials.J. Pain Symptom Manage.2018552468479.e110.1016/j.jpainsymman.2017.08.02228919541
     [Google Scholar]
  85. LeppertW. WoronJ. The role of naloxegol in the management of opioid-induced bowel dysfunction.Therap. Adv. Gastroenterol.20169573674610.1177/1756283X1664886927582887
     [Google Scholar]
  86. Culpepper-MorganJ.A. InturrisiC.E. PortenoyR.K. FoleyK. HoudeR.W. MarshF. KreekM.J. Treatment of opioid-induced constipation with oral naloxone: A pilot study.Clin. Pharmacol. Ther.1992521909510.1038/clpt.1992.1061623695
     [Google Scholar]
  87. WaldA. Update on the management of constipation.JAMA2019322222239224010.1001/jama.2019.1602931682683
     [Google Scholar]
  88. ChamberlainB.H. CrossK. WinstonJ.L. ThomasJ. WangW. SuC. IsraelR.J. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness.J. Pain Symptom Manage.200938568369010.1016/j.jpainsymman.2009.02.23419713070
     [Google Scholar]
  89. IyerS.S. RandazzoB.P. TzanisE.L. SchulmanS.L. ZhangH. WangW. ManleyA.L. Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms.Value Health201114117718310.1016/j.jval.2010.11.00321211500
     [Google Scholar]
  90. TsurudaP.R. VickeryR.G. LongD.D. ArmstrongS.R. BeattieD.T. The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist.Naunyn Schmiedebergs Arch. Pharmacol.2013386647949110.1007/s00210‑013‑0850‑723549670
     [Google Scholar]
  91. ArmstrongS.R. CampbellC.B. RichardsonC.L. VickeryR.G. TsurudaP.R. LongD.D. HegdeS.S. BeattieD.T. The in vivo pharmacodynamics of the novel opioid receptor antagonist, TD-1211, in models of opioid-induced gastrointestinal and CNS activity.Naunyn Schmiedebergs Arch. Pharmacol.2013386647147810.1007/s00210‑013‑0844‑523512167
     [Google Scholar]
  92. VickeryR. WebsterL. LiY. SinglaN. CanafaxD. (406) Axelopran phase 2B study demonstrates a sustained increase in bowel movement frequency in patients regardeless of duration of opioid-induced constipation.J. Pain2014154S7710.1016/j.jpain.2014.01.317
     [Google Scholar]
  93. ColuzziF. ScerpaM.S. PergolizziJ. Naldemedine: A new option for OIBD.J. Pain Res.2020131209122210.2147/JPR.S24343532547183
     [Google Scholar]
  94. OhnishiS. FukumuraK. KubotaR. WajimaT. Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects.Xenobiotica20194991044105310.1080/00498254.2018.153681530351180
     [Google Scholar]
  95. BlairH.A. Naldemedine: A review in opioid-induced constipation.Drugs201979111241124710.1007/s40265‑019‑01160‑731267482
     [Google Scholar]
  96. InagakiM. KumeM. TamuraY. HaraS. GotoY. HagaN. HasegawaT. NakamuraT. KoikeK. OonishiS. KanemasaT. KaiH. Discovery of naldemedine: A potent and orally available opioid receptor antagonist for treatment of opioid-induced adverse effects.Bioorg. Med. Chem. Lett.2019291737710.1016/j.bmcl.2018.11.00730446313
     [Google Scholar]
  97. WatariR. MatsudaA. OhnishiS. HasegawaH. Minimal contribution of P-gp on the low brain distribution of naldemedine, a peripherally acting μ-opioid receptor antagonist.Drug Metab. Pharmacokinet.201934212613310.1016/j.dmpk.2018.12.00230770183
     [Google Scholar]
  98. KanemasaT. KoikeK. AraiT. OnoH. HoritaN. ChibaH. NakamuraA. MoriokaY. KiharaT. HasegawaM. Pharmacologic effects of naldemedine, a peripherally acting μ-opioid receptor antagonist, in in vitro and in vivo models of opioid-induced constipation.Neurogastroenterol. Motil.2019315e1356310.1111/nmo.1356330821019
     [Google Scholar]
  99. FukumuraK. YokotaT. BabaY. Arjona FerreiraJ.C. Phase 1, randomized, double-blind, placebo-controlled studies on the safety, tolerability, and pharmacokinetics of naldemedine in healthy volunteers.Clin. Pharmacol. Drug Dev.20187547448310.1002/cpdd.38728960888
     [Google Scholar]
  100. WebsterL.R. YamadaT. Arjona FerreiraJ.C. A phase 2b, randomized, double-blind placebo-controlled study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation in patients with chronic noncancer pain.Pain Med.201718122350236010.1093/pm/pnw32528371937
     [Google Scholar]
  101. Efficacy and safety of naldemedine in the treatment of opioid-induced constipation.2017Available from: https://www.clinicaltrials.gov/ct2/show/NCT01965158 (Accessed on: 10 Feb 2022).
  102. Long term safety of naldemedine.Available from: https://www.clinicaltrials.gov/ct2/show/NCT01965652 (Accessed on: 10 Feb 2022).
  103. McWilliamsV. WhitesideG. McKeageK. Linaclotide.Drugs201272162167217510.2165/11470590‑000000000‑0000023083112
     [Google Scholar]
  104. BryantA.P. BusbyR.W. BartoliniW.P. CorderoE.A. HannigG. KesslerM.M. PierceC.M. SolingaR.M. TobinJ.V. Mahajan-MiklosS. CohenM.B. KurtzC.B. CurrieM.G. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract.Life Sci.20108619-2076076510.1016/j.lfs.2010.03.01520307554
     [Google Scholar]
  105. BassottiG. Usai SattaP. BelliniM. Prucalopride for the treatment of constipation: A view from 2015 and beyond.Expert Rev. Gastroenterol. Hepatol.201913325726210.1080/17474124.2019.156823830791758
     [Google Scholar]
  106. QuigleyE.M.M. Prucalopride: Safety, efficacy and potential applications.Therap. Adv. Gastroenterol.201251233010.1177/1756283X1142370622282705
     [Google Scholar]
  107. ZuoL. SunZ. WangZ. DuS. KongX. LiL. YangJ. KangJ. ZhangX. Pharmacokinetics and tissue distribution study of prucalopride in rats by ultra high performance liquid chromatography with tandem mass spectrometry.J. Pharm. Biomed. Anal.201613124625510.1016/j.jpba.2016.08.03027611096
     [Google Scholar]
  108. CarboneF. Van den HouteK. CleversE. AndrewsC.N. PapathanasopoulosA. HolvoetL. Van OudenhoveL. CaenepeelP. ArtsJ. VanuytselT. TackJ. Prucalopride in gastroparesis: A randomized placebo-controlled crossover study.Am. J. Gastroenterol.201911481265127410.14309/ajg.000000000000030431295161
     [Google Scholar]
  109. CamilleriM. KerstensR. RykxA. VandeplasscheL. A placebo-controlled trial of prucalopride for severe chronic constipation.N. Engl. J. Med.2008358222344235410.1056/NEJMoa080067018509121
     [Google Scholar]
  110. HolderR.M. RheeD. Novel oral therapies for opioid-induced bowel dysfunction in patients with chronic noncancer pain.Pharmacotherapy201636328729910.1002/phar.171126945548
     [Google Scholar]
  111. CryerB. KatzS. VallejoR. PopescuA. UenoR. A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain.Pain Med.201415111825183410.1111/pme.1243724716835
     [Google Scholar]
  112. DrossmanD.A. CheyW.D. JohansonJ.F. FassR. ScottC. PanasR. UenoR. Clinical trial: Lubiprostone in patients with constipation-associated irritable bowel syndrome - Results of two randomized, placebo-controlled studies.Aliment. Pharmacol. Ther.200929332934110.1111/j.1365‑2036.2008.03881.x19006537
     [Google Scholar]
  113. RekatsinaM. PaladiniA. DrewesA.M. AyobF. ViswanathO. UritsI. CorliO. PergolizziJ.Jr VarrassiG. Efficacy and safety of peripherally acting μ-opioid receptor antagonist (PAMORAs) for the management of patients with opioid-induced constipation: A systematic review.Cureus2021137e1620110.7759/cureus.1620134367804
     [Google Scholar]
/content/journals/cis/10.2174/2210299X01666220902112122
Loading
A State-of-the-Art Review on Opioids Induced Constipation and its Management
Curr. Indian Sci. 1, e020922208451 (2023); https://doi.org/10.2174/2210299X01666220902112122
/content/journals/cis/10.2174/2210299X01666220902112122
/content/journals/cis/10.2174/2210299X01666220902112122
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Opioid antagonists; Opioid inhibitors; Opioid receptors; Opioid-induced constipation; Opioids; Pain

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test